Literature DB >> 31030544

High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

Xiaoming Jia1, Wensheng Sun1, Ron C Hoogeveen1, Vijay Nambi1,2, Kunihiro Matsushita3, Aaron R Folsom4, Gerardo Heiss5, David J Couper5, Scott D Solomon6, Eric Boerwinkle7, Amil Shah6, Elizabeth Selvin3, James A de Lemos8, Christie M Ballantyne1.   

Abstract

BACKGROUND: We assessed whether plasma troponin I measured by a high-sensitivity assay (hs-TnI) is associated with incident cardiovascular disease (CVD) and mortality in a community-based sample without prior CVD.
METHODS: ARIC study (Atherosclerosis Risk in Communities) participants aged 54 to 74 years without baseline CVD were included in this study (n=8121). Cox proportional hazards models were constructed to determine associations between hs-TnI and incident coronary heart disease (CHD; myocardial infarction and fatal CHD), ischemic stroke, atherosclerotic CVD (CHD and stroke), heart failure hospitalization, global CVD (atherosclerotic CVD and heart failure), and all-cause mortality. The comparative association of hs-TnI and high-sensitivity troponin T with incident CVD events was also evaluated. Risk prediction models were constructed to assess prediction improvement when hs-TnI was added to traditional risk factors used in the Pooled Cohort Equation.
RESULTS: The median follow-up period was ≈15 years. Detectable hs-TnI levels were observed in 85% of the study population. In adjusted models, in comparison to low hs-TnI (lowest quintile, hs-TnI ≤1.3 ng/L), elevated hs-TnI (highest quintile, hs-TnI ≥3.8 ng/L) was associated with greater incident CHD (hazard ratio [HR], 2.20; 95% CI, 1.64-2.95), ischemic stroke (HR, 2.99; 95% CI, 2.01-4.46), atherosclerotic CVD (HR, 2.36; 95% CI, 1.86-3.00), heart failure hospitalization (HR, 4.20; 95% CI, 3.28-5.37), global CVD (HR, 3.01; 95% CI, 2.50-3.63), and all-cause mortality (HR, 1.83; 95% CI, 1.56-2.14). hs-TnI was observed to have a stronger association with incident global CVD events in white than in black individuals and a stronger association with incident CHD in women than in men. hs-TnI and high-sensitivity troponin T were only modestly correlated ( r=0.47) and were complementary in prediction of incident CVD events, with elevation of both troponins conferring the highest risk in comparison with elevation in either one alone. The addition of hs-TnI to the Pooled Cohort Equation model improved risk prediction for atherosclerotic CVD, heart failure, and global CVD.
CONCLUSIONS: Elevated hs-TnI is strongly associated with increased global CVD incidence in the general population independent of traditional risk factors. hs-TnI and high-sensitivity troponin T provide complementary rather than redundant information.

Entities:  

Keywords:  biomarkers; cardiovascular diseases; troponin I

Mesh:

Substances:

Year:  2019        PMID: 31030544      PMCID: PMC6546524          DOI: 10.1161/CIRCULATIONAHA.118.038772

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  Estimation of time-dependent area under the ROC curve for long-term risk prediction.

Authors:  Lloyd E Chambless; Guoqing Diao
Journal:  Stat Med       Date:  2006-10-30       Impact factor: 2.373

2.  Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study.

Authors:  S E Reis; R Holubkov; A J Conrad Smith; S F Kelsey; B L Sharaf; N Reichek; W J Rogers; C N Merz; G Sopko; C J Pepine
Journal:  Am Heart J       Date:  2001-05       Impact factor: 4.749

3.  N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

Authors:  Michael H Olsen; Tine W Hansen; Marina K Christensen; Finn Gustafsson; Susanne Rasmussen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Per R Hildebrandt
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

4.  Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays.

Authors:  Q Shi; M Ling; X Zhang; M Zhang; L Kadijevic; S Liu; J P Laurino
Journal:  Clin Chem       Date:  1999-07       Impact factor: 8.327

5.  Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study).

Authors:  Laura R Loehr; Wayne D Rosamond; Patricia P Chang; Aaron R Folsom; Lloyd E Chambless
Journal:  Am J Cardiol       Date:  2008-02-14       Impact factor: 2.778

Review 6.  Multiple molecular forms of circulating cardiac troponin: analytical and clinical significance.

Authors:  David C Gaze; Paul O Collinson
Journal:  Ann Clin Biochem       Date:  2008-07       Impact factor: 2.057

7.  Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis.

Authors:  Seung Hwan Han; Jang Ho Bae; David R Holmes; Ryan J Lennon; Eric Eeckhout; Gregory W Barsness; Charanjit S Rihal; Amir Lerman
Journal:  Eur Heart J       Date:  2008-04-18       Impact factor: 29.983

8.  Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study.

Authors:  Anna M Kucharska-Newton; David J Couper; James S Pankow; Ronald J Prineas; Thomas D Rea; Nona Sotoodehnia; Aravinda Chakravarti; Aaron R Folsom; David S Siscovick; Wayne D Rosamond
Journal:  Acta Diabetol       Date:  2009-10-24       Impact factor: 4.280

9.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

10.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  47 in total

1.  Associations Between Dietary Patterns and Subclinical Cardiac Injury: An Observational Analysis From the DASH Trial.

Authors:  Stephen P Juraschek; Lara C Kovell; Lawrence J Appel; Edgar R Miller; Frank M Sacks; Robert H Christenson; Heather Rebuck; Alexander R Chang; Kenneth J Mukamal
Journal:  Ann Intern Med       Date:  2020-05-19       Impact factor: 25.391

2.  Cardiac Troponin I and Risk of Stroke: A Mendelian Randomization Study.

Authors:  Heng Chen; Xingang Sun; Chengui Zhuo; Jianqiang Zhao; Aohan Zu; Qiqi Wang; Liangrong Zheng
Journal:  Int J Gen Med       Date:  2022-02-15

3.  Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study).

Authors:  Christopher W Puleo; Colby R Ayers; Sonia Garg; Ian J Neeland; Alana A Lewis; Ambarish Pandey; Mark H Drazner; James A de Lemos
Journal:  Biomark Med       Date:  2021-10-19       Impact factor: 2.851

4.  Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study".

Authors:  Xiaoming Jia; Wensheng Sun; Ron C Hoogeveen; Vijay Nambi; Kunihiro Matsushita; Aaron R Folsom; Gerardo Heiss; David J Couper; Scott D Solomon; Eric Boerwinkle; Amil Shah; Elizabeth Selvin; James A de Lemos; Christie M Ballantyne
Journal:  Circulation       Date:  2019-11-11       Impact factor: 29.690

Review 5.  Risk-Based Approach for the Prediction and Prevention of Heart Failure.

Authors:  Arjun Sinha; Deepak K Gupta; Clyde W Yancy; Sanjiv J Shah; Laura J Rasmussen-Torvik; Elizabeth M McNally; Philip Greenland; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Circ Heart Fail       Date:  2021-02-04       Impact factor: 8.790

6.  Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study).

Authors:  Aliza Hussain; Olive Tang; Caroline Sun; Xiaoming Jia; Elizabeth Selvin; Vijay Nambi; Aaron Folsom; Gerardo Heiss; Faiez Zannad; Thomas Mosley; Salim S Virani; Josef Coresh; Eric Boerwinkle; Bing Yu; Jonathan W Cunningham; Amil M Shah; Scott D Solomon; James A de Lemos; Ron C Hoogeveen; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2021-02-02       Impact factor: 2.778

Review 7.  Advancements in biomarkers for cardiovascular disease: diagnosis, prognosis, and therapy.

Authors:  Nicholas Wettersten; Yu Horiuchi; Alan Maisel
Journal:  Fac Rev       Date:  2021-03-31

8.  Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life.

Authors:  Aaron J Cohen; Kanako Teramoto; Brian Claggett; Leo Buckley; Scott Solomon; Christie Ballantyne; Elizabeth Selvin; Amil M Shah
Journal:  J Card Fail       Date:  2021-07-25       Impact factor: 5.712

9.  The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review.

Authors:  Ty Sweeney; Renato Quispe; Thomas Das; Stephen P Juraschek; Seth S Martin; Erin D Michos
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-05-26

Review 10.  The ARIC (Atherosclerosis Risk In Communities) Study: JACC Focus Seminar 3/8.

Authors:  Jacqueline D Wright; Aaron R Folsom; Josef Coresh; A Richey Sharrett; David Couper; Lynne E Wagenknecht; Thomas H Mosley; Christie M Ballantyne; Eric A Boerwinkle; Wayne D Rosamond; Gerardo Heiss
Journal:  J Am Coll Cardiol       Date:  2021-06-15       Impact factor: 27.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.